A Randomized, Double-blind, Placebo-controlled, Multi-national, Multi-center, Parallel-group, Phase 2b Assessing ART-123's Effect on Preventing Sensory Symptoms of OIPN in Unresectable mCRC Subjects Receiving Oxaliplatin-containing Chemo
Latest Information Update: 22 Feb 2022
At a glance
- Drugs Thrombomodulin alfa (Primary)
- Indications Chemotherapy-induced damage; Peripheral neuropathies
- Focus Therapeutic Use
- Sponsors Asahi Kasei Pharma America Corp; Veloxis Pharmaceuticals
- 02 Feb 2022 Status changed from not yet recruiting to withdrawn prior to enrolment as study design was changed.
- 05 Aug 2021 Planned initiation date changed from 1 Jul 2021 to 1 Oct 2021.
- 28 Jan 2021 Planned initiation date changed from 1 Nov 2020 to 1 Jul 2021.